Prognostic Value Of Cancer Stem Cell Marker Cd133 In Ovarian Cancer: A Meta-Analysis

Objective: To investigate the association between CD133 expression and prognosis and clinicopathological features of ovarian cancer. Methods: The electronic and manual searches were performed through the database of PubMed Chinese Wanfang databases (up to September 15, 2014) was performed using the following keywords ovarian cancer, CD133, AC133, prominin-1. Meta-analysis was performed by using Review Manager 5.2 and the outcomes included the overall survival and various clinicopathological features. Results: A total of 1051 ovarian cancer patients from 8 studies were included. Meta-analysis showed that overexpression of CD133 was highly correlated with reduced 2-year overall survival (OR = 1.67, 95% CI: 1.06-2.63, P = 0.03, fixed-effect). With respect to clinicopathological features, CD133 level was positively correlated with tumor stage (OR = 0.26, 95% CI: 0.12-0.58, P = 0.001 random-effect). But not correlated with patients' age (OR = 1.12, 95% CI: 0.68-1.86, P = 0.65 fixed-effect), tumor grade (OR = 1.20, 95% CI: 0.06-1.62, P = 0.17 random-effect), histological type (OR = 1.10, 95% CI: 0.82-1.47, P = 0.54 fixed-effect) and response to treatment (OR = 0.84, 95% CI: 0.61-1.16, P = 0.29 fixed-effect). Conclusion: On the basis of current retrospective evidence, the present meta-analysis indicated that high level of CD133 expression trends to correlate with a worse prognosis in patients with ovarian cancer.